Premium
A novel recombinant Salmonella vaccine enhances the innate immunity of NK cells against acute myeloid leukaemia cells Kasumi‐1 in vitro
Author(s) -
Zhang Bei,
Liu Yuan,
Wang Xiuju,
Jiang Ling,
Lu Zhigang,
Zhang Xing,
Li Kunpeng,
Hu Haiyan
Publication year - 2013
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.10173
Subject(s) - cytotoxic t cell , innate immune system , biology , recombinant dna , virology , in vitro , microbiology and biotechnology , immunology , immune system , gene , biochemistry
Abstract Minor histocompatibility antigen HA‐1‐specific cytotoxic lymphocyte (CTL) clones have apparent anti‐leukaemic efficacy, and the AML/ETO gene is a special fusion gene in leukaemic cells. Thus, we hypothesised that a vaccine targeting HA‐1 and AML/ETO could stimulate NK cells to target leukaemia cells. Furthermore, we packaged the vaccine using attenuated Salmonella to enhance its immuno‐activity. Expression of the NK cell‐activating ligand ULBP2 was notably elevated upon packaging in a co‐recombinant group. An AML/ETO single plasmid gave the weakest vaccine. The level of miR‐182, which targets ULBP2, significantly decreased with increasing IFN‐γ and granzyme B in a co‐recombinant group. In summary, DNA vaccines including AML/ETO and HA‐1 fragments significantly enhance the innate immunity of NK cells in vitro.